The Breast Friends Podcast posted on LinkedIn:
“In the curative setting, safety is the crux.
Building on the KEYNOTE-756 clinical implications, Dr. Jason A. Mouabbi and Dr. Paolo Tarantino discuss why combining immunotherapy with CDK4/6 inhibitors isn’t ready for prime time.
The goal is improving outcomes through tailored care, not creating additional toxicity.
If cure is the goal, treatment can’t become the problem.
Watch on YouTube
Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, & Amazon Music.”
Proceed to watch the video attached to the post.
Other articles featuring Paolo Tarantino on OncoDaily.